Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Buniva

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of diseaseA Berruti, M Tampellini, M Torta, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|June 1, 1991
Exogenous melatonin enhances the TRH-induced prolactin release in normally cycling women: a sex-specific effectM Terzolo, A Piovesan, G Osella, et al.
Chronobiology International|January 1, 1990
Circadian profile of serum melatonin in Cushing's disease and acromegalyA Piovesan, M Terzolo, G Borretta, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 20, 1990
Melatonin and human cancerL Dogliotti, A Berruti, T Buniva, et al.
Cancer Chemotherapy and Pharmacology|March 6, 1998
Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot studyL Dogliotti, S Danese, A Berruti, et al.
British Journal of Cancer|January 1, 1997
Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic diseaseM Tampellini, A Berruti, A Gerbino, et al.
Tumori|June 10, 1998
Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastasesD Fontana, O Bertetto, G Fasolis, et al.
Anticancer Research|July 1, 1997
Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survivalA Berruti, P Zola, T Buniva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trialL Dogliotti, A Berruti, T Buniva, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of diseaseA Berruti, M Tampellini, M Torta, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|June 1, 1991
Exogenous melatonin enhances the TRH-induced prolactin release in normally cycling women: a sex-specific effectM Terzolo, A Piovesan, G Osella, et al.
Chronobiology International|January 1, 1990
Circadian profile of serum melatonin in Cushing's disease and acromegalyA Piovesan, M Terzolo, G Borretta, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 20, 1990
Melatonin and human cancerL Dogliotti, A Berruti, T Buniva, et al.
Cancer Chemotherapy and Pharmacology|March 6, 1998
Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot studyL Dogliotti, S Danese, A Berruti, et al.
British Journal of Cancer|January 1, 1997
Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic diseaseM Tampellini, A Berruti, A Gerbino, et al.
Tumori|June 10, 1998
Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastasesD Fontana, O Bertetto, G Fasolis, et al.
Anticancer Research|July 1, 1997
Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survivalA Berruti, P Zola, T Buniva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trialL Dogliotti, A Berruti, T Buniva, et al.
Pageof 1